Subscribe To
BCYC / Here's Why Bicycle Therapeutics Stock Looks Ill Today
BCYC News
By Zacks Investment Research
September 12, 2023
Bicycle (BCYC) to Begin Pivotal Bladder Cancer Study, Stock Up
Bicycle (BCYC) aligns with the FDA on the design of a mid-late-stage registrational study for its bladder cancer drug, BT8009, with the potential to s more_horizontal
By Zacks Investment Research
September 12, 2023
Bicycle Therapeutics PLC Sponsored ADR (BCYC) Surges 9.0%: Is This an Indication of Further Gains?
Bicycle Therapeutics PLC Sponsored ADR (BCYC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimat more_horizontal
By The Motley Fool
September 11, 2023
Why Shares of Bicycle Therapeutics Were Rising on Monday
Bicycle Therapeutics has 14 programs in its pipeline. The company is a clinical-stage biotech. more_horizontal
By Seeking Alpha
July 31, 2023
Bicycle Therapeutics: Decent Upside Opportunity, Mid-Stage Data Readouts Due
Bicycle Therapeutics is an intriguing play in the drug development space. Using its fully synthetic short peptides, the company has developed two mid- more_horizontal
By Zacks Investment Research
July 14, 2023
Bicycle Therapeutics PLC Sponsored ADR (BCYC) Soars 19.3%: Is Further Upside Left in the Stock?
Bicycle Therapeutics PLC Sponsored ADR (BCYC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimat more_horizontal
By The Motley Fool
July 13, 2023
Why Bicycle Therapeutics Stock Raced Ahead Today
The U.K.-based biotech announced a fresh offering of its ADSes. It's seeking to net around $187 million in proceeds with the issue. more_horizontal
By Seeking Alpha
May 14, 2023
Bicycle Therapeutics: Not Much Differentiation Between Bicycles And mAbs Yet
BCYC's distinction is that it is founded by a Nobel laureate. However, unless it can differentiate its product's efficacy from that of mAbs, that may more_horizontal
By Zacks Investment Research
May 4, 2023
Wall Street Analysts Think Bicycle Therapeutics PLC Sponsored ADR (BCYC) Could Surge 146.31%: Read This Before Placing a Bet
The consensus price target hints at a 146.3% upside potential for Bicycle Therapeutics PLC Sponsored ADR (BCYC). While empirical research shows that t more_horizontal